亞太地區免疫診斷市場預測至 2030 年 - 區域分析 - 按產品（酵素連結免疫吸附測定、化學發光免疫測定、放射免疫測定等）、臨床適應症和最終用戶

亞太免疫診斷市場預計將從2023年的24.099億美元成長到2030年的42.5235億美元。預計2023年至2030年CAGR為8.5%。

免疫診斷技術進步推動亞太工業機器人市場

當前免疫診斷的趨勢是具有商業化潛力的微流控和磁珠。這些敏感、具體且節省時間的方法對於理解和診斷健康狀況（例如傳染病、代謝紊亂和心臟問題）至關重要。

免疫診斷解決方案的不斷增加的應用鼓勵了針對精準健康的標靶治療和療法的開發。著名的市場參與者也推廣檢測技術、微流體和磁珠。對於免疫測定，磁性顆粒（例如 Sera-Mag 磁珠）為基於板的 ELISA 提供了便捷的替代方案，因為兩者都依賴相同的測定原理。 Merck KGaA 推出了 Magna Chip Protein A 磁珠。這種重組蛋白 A 與磁珠共價結合，用於染色質免疫沉澱（晶片測定），為使用者提供比瓊脂糖微珠更快、可重複且更有效的免疫複合物收集試劑。

在微流體學中，一些免疫診斷針對單一生物標記。然而，最近的趨勢表明，根據複雜性和早期可靠診斷的需要，可以檢測多種分析物。

2023 年 9 月，西門子 Healthineers 發布了帶有 CE 標誌的新型 SARS-CoV-2/FluA/FluB/HRSV 檢測、PCR 檢測以及 CLINITEST 快速 COVID-19 + 流感抗原檢測。新的 FTD SARS-CoV-2/FluA/FluB/HRSV 檢測能夠對季節性呼吸道病原體進行全面、半自動化的分子檢測。組合 PCR 測試可檢測和區分臨床相關病毒，例如 SARS-CoV-2、甲型流感、乙型流感和 HRSV A/B。

亞太地區免疫診斷市場概況

根據Statista統計，2020年中國很大一部分人口患有慢性病。中國60歲以上人口死亡中近80%是由慢性非傳染性疾病引起，其中最嚴重的是缺血性心臟病、中風、慢性阻塞性肺病(COPD) 和II 型糖尿病。根據《中國藍圖》顯示，免疫診斷已超過生化診斷（佔27%），體外診斷（IVD）市場已成為中國主流。但與已開發國家相比，我國免疫診斷市場的替代生化診斷仍有拓展空間，根據多家機構的統計資料，生化與免疫診斷的平均比例約為1：2。隨著技術創新的進步以及對高階測試的需求不斷成長，診斷預計將鞏固其主流地位。

此外，組織之間在開發和生產檢測方法方面的合作正在不斷增加。例如，2023 年 12 月，Ortho Clinical Diagnostics Trading 和上海麥康生物技術有限公司簽署了一項協議，作為合資企業的一部分，在中國開發和製造 VITROS 免疫診斷平台的檢測方法。 Ortho Clinical Diagnostics Trading 在開發和設計用於 POC 設置、臨床實驗室和輸血醫學的體外診斷 (IVD) 技術方面的專業知識將推動亞太地區免疫診斷市場在未來幾年的成長。

亞太地區免疫診斷市場收入及 2030 年預測（百萬美元）

亞太地區免疫診斷市場細分

亞太地區免疫診斷市場分為產品、臨床適應症、最終用戶和國家。

根據產品，亞太免疫診斷市場分為酵素連結免疫吸附測定（ELISA）、化學發光免疫測定（CLIA）、放射免疫測定（RIA）等。 2023年，酵素連結免疫吸附測定（ELISA）領域在亞太免疫診斷市場中佔據最大佔有率。化學發光免疫分析 (CLIA) 領域進一步細分為維生素 D 分析市場、HIV 檢測市場、HIV a/ab 組合分析市場和其他測試。

根據臨床適應症，亞太免疫診斷市場分為傳染病、愛滋病毒、內分泌、胃腸道、代謝等。 2023年，傳染病領域在亞太免疫診斷市場中佔據最大佔有率。傳染病細分為 COVID-19、結核病、萊姆病、感染管理、寨卡病毒、密螺旋體、火炬、麻疹和腮腺炎、水痘帶狀皰疹病毒和 EB 病毒。內分泌科進一步細分為高血壓、生長、糖尿病、甲狀腺和生殖內分泌。

根據最終用戶，亞太地區免疫診斷市場分為醫院、診所、診斷實驗室、學術和研究機構等。 2023年，醫院細分市場在亞太免疫診斷市場中佔據最大佔有率。

依國家/地區分類，亞太地區免疫診斷市場分為中國、日本、印度、澳洲、韓國和亞太地區其他地區。 2023年，中國在亞太免疫診斷市場中佔最大佔有率。

雅培實驗室；生物梅里埃公司；丹納赫公司； DiaSorin SpA； F.霍夫曼-拉羅氏有限公司；珀金埃爾默公司；深圳邁瑞生物醫療電子有限公司；西門子醫療保健有限公司；斯瓦爾生命科學公司；和 Thermo Fisher Scientific Inc 是亞太地區免疫診斷市場上的一些領先公司。

概述
按臨床適應症分類的亞太地區免疫診斷市場佔有率 - 2022 年和 2030 年 (%)
傳染性疾病：
- 概述
  - 新冠肺炎
  - 結核
  - 萊姆病
  - 感染管理
  - 寨卡病毒
  - 密螺旋體屬
  - 火炬
  - 麻疹和腮腺炎
  - VZV
  - EB病毒
肝炎+愛滋病毒：
- 概述
胃腸道
- 概述
代謝紊亂
- 概述
內分泌科
- 概述
- 高血壓
  - 概述
- 生長
  - 概述
- 糖尿病
  - 概述
- 甲狀腺
  - 概述
- 生殖內分泌學
  - 概述
其他
- 概述

第 9 章：亞太地區免疫診斷市場分析 - 最終用戶

概述
按最終用戶分類的亞太地區免疫診斷市場佔有率 - 2022 年和 2030 年 (%)
醫院
- 概述
診所
- 概述
診斷實驗室
- 概述
學術及研究機構
- 概述
其他
- 概述

第 10 章：亞太地區免疫診斷市場 - 2030 年收入與預測 - 國家分析

概述

第 11 章：亞太地區免疫診斷市場 - 產業格局

概述
無機成長策略
- 概述
有機成長策略
- 概述

第 12 章：公司簡介

Abbott Laboratories
F. Hoffmann-La Roche Ltd
DiaSorin SpA
Danaher Corp
Thermo Fisher Scientific Inc
PerkinElmer Inc
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
bioMerieux SA
Svar Life Science AB
Siemens Healthcare GmbH

第 13 章：附錄

關於 Insight Partners
專業術語

Product Code: BMIRE00027857

The Asia Pacific immunodiagnostics market is expected to grow from US$ 2,409.90 million in 2023 to US$ 4,252.35 million by 2030. It is estimated to grow at a CAGR of 8.5% from 2023 to 2030.

Technological Advancements in Immunodiagnostics Drive Asia Pacific Industrial Robotics Market

The current trend in immunodiagnostics is microfluidics and magnetic beads with potential commercialization. These sensitive, specific, and time-saving methodologies are essential in understanding and diagnosing health conditions, such as infectious diseases, metabolic disorders, and cardiac problems.

The increasing applications of immunodiagnostics solutions encouraged the development of targeted treatments and therapies for precision health. The prominent market players also promote assay technologies, microfluidics, and magnetic beads. For immunoassays, magnetic particles, such as Sera-Mag beads, offer a convenient alternative to plate-based ELISAs, as both rely on the same assay principle. Merck KGaA launched the Magna Chip Protein A magnetic beads. This recombinant Protein A is covalently bound to magnetic beads for chromatin immunoprecipitations (Chip assays), providing users with a faster, reproducible, and more efficient reagent for collecting immunocomplexes than agarose beads.

In microfluidics, some immunodiagnostics target single biomarkers. However, a recent trend shows the detection of multiple analytes according to the complexity and the need to make early reliable diagnoses.

In September 2023, Siemens Healthineers released its new CE-marked SARS-CoV-2/FluA/FluB/HRSV assay, a PCR test, and the CLINITEST Rapid COVID-19 + Influenza Antigen Test. The new FTD SARS-CoV-2/FluA/FluB/HRSV assay enables comprehensive and semi-automated molecular testing for seasonal respiratory pathogens. The combination PCR test detects and differentiates clinically relevant viruses such as SARS-CoV-2, Influenza A, Influenza B, and HRSV A/B.

Asia Pacific Immunodiagnostics Market Overview

According to Statista, a large chunk of the Chinese population was suffering from chronic diseases in 2020. Almost 80% of deaths among people aged 60 years in the country are caused due to chronic NCDs, of which the most severe are ischemic heart disease, stroke, chronic obstructive pulmonary disease (COPD), and Type II diabetes. According to China Blueprint, immunological diagnosis has exceeded biochemical diagnosis (accounting for 27%), and the in vitro diagnostics (IVD) market has gone mainstream in China. However, compared to developed countries, there is still room for alternative biochemical diagnosis to expand in China's immunodiagnostics market, as the average ratio of biochemical to immunization diagnosis is about 1:2, according to statistical data from several agencies. As technological innovation advances with the growing need for high-end testing, diagnostics is expected to consolidate its mainstream status.

Furthermore, collaborations between organizations are increasing for developing and producing assays. For instance, in December 2023, Ortho Clinical Diagnostics Trading and Shanghai Medconn Biotechnology signed an agreement as part of a joint venture to develop and manufacture assays for the VITROS immunodiagnostics platform in China. The expertise of Ortho Clinical Diagnostics Trading in developing and designing in vitro diagnostics (IVD) technologies for POC settings, clinical labs, and transfusion medicine will propel the growth of the Asia Pacific immunodiagnostics market in the coming years.

Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Immunodiagnostics Market Segmentation

The Asia Pacific immunodiagnostics market is segmented into product, clinical indication, end user, and country.

Based on product, the Asia Pacific immunodiagnostics market is segmented into enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays (CLIA), radioimmunoassays (RIA), and others. In 2023, the enzyme-linked immunosorbent assays (ELISA) segment registered a largest share in the Asia Pacific immunodiagnostics market. The chemiluminescence immunoassays (CLIA) segment is further segmented into vitamin D assay market, HIV detection market, HIV ag/ab combo assay market, and other tests.

Based on clinical indication, the Asia Pacific immunodiagnostics market is segmented into infectious diseases, hepatitis HIV, endocrinology, gastrointestinal, metabolics, and others. In 2023, the infectious diseases segment registered a largest share in the Asia Pacific immunodiagnostics market. The infectious diseases segment is further segmented into COVID-19, tuberculosis, lyme, infection management, zika, treponema, torch, measles and mumps, VZV, and EBV. The endocrinology segment is further segmented into hypertension, growth, diabetes, thyroid, and reproductive endocrinology.

Based on end user, the Asia Pacific immunodiagnostics market is segmented into hospitals, clinics, diagnostic laboratories, academic & research institutes, and others. In 2023, the hospitals segment registered a largest share in the Asia Pacific immunodiagnostics market.

Based on country, the Asia Pacific immunodiagnostics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. In 2023, China registered a largest share in the Asia Pacific immunodiagnostics market.

Abbott Laboratories; bioMerieux SA; Danaher Corp; DiaSorin SpA; F. Hoffmann-La Roche Ltd; PerkinElmer Inc; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; Siemens Healthcare GmbH; Svar Life Science AB; and Thermo Fisher Scientific Inc are some of the leading companies operating in the Asia Pacific immunodiagnostics market.

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific immunodiagnostics market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific immunodiagnostics market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the immunodiagnostics market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
- 1.3.1 Asia Pacific Immunodiagnostics Market - by Product
- 1.3.2 Asia Pacific Immunodiagnostics Market - by Clinical Indication
- 1.3.3 Asia Pacific Immunodiagnostics Market - by End User
- 1.3.4 Asia Pacific Immunodiagnostics Market - by Country

2. Asia Pacific Immunodiagnostics Market - Key Takeaways

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific Immunodiagnostics Market - Market Landscape

4.1 Overview
4.2 Asia Pacific PEST Analysis
4.3 Expert's Opinion

5. Asia Pacific Immunodiagnostics Market - Key Market Dynamics

5.1 Market Drivers
- 5.1.1 Increasing Prevalence of Infectious Diseases
- 5.1.2 Growing Use of Point-of-Care Immunodiagnostics
5.2 Market Restraints
- 5.2.1 Inadequate Reimbursement Scenario
5.3 Market Opportunities
- 5.3.1 Rising Focus on R&D Investment and Expansion by Key Players
5.4 Future Trends
- 5.4.1 Technological Advancements in Immunodiagnostics
5.5 Impact Analysis

6. Immunodiagnostics Market - Asia Pacific Analysis

6.1 Asia Pacific Immunodiagnostics Market Revenue Forecast and Analysis

7. Asia Pacific Immunodiagnostics Market Analysis - by Product

7.1 Overview
7.2 Asia Pacific Immunodiagnostics Market, By Product, 2022 & 2030 (%)
7.3 Enzyme-linked Immunosorbent Assays (ELISA)
- 7.3.1 Overview
- 7.3.2 Enzyme-linked Immunosorbent Assays (ELISA): Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.4 Chemiluminescence Immunoassays (CLIA)
- 7.4.1 Overview
- 7.4.2 Chemiluminescence Immunoassays (CLIA): Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 7.4.3 Vitamin D Assay
  - 7.4.3.1 Overview
  - 7.4.3.2 Vitamin D Assay: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 7.4.4 HIV Detection
  - 7.4.4.1 Overview
  - 7.4.4.2 HIV Detection: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 7.4.5 HIV Ag/Ab Combo assay
  - 7.4.5.1 Overview
  - 7.4.5.2 HIV Ag/Ab Combo Assay: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 7.4.6 Other Tests
  - 7.4.6.1 Overview
  - 7.4.6.2 Other Tests: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.5 Radioimmunoassays (RIA)
- 7.5.1 Overview
- 7.5.2 Radioimmunoassays (RIA): Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Immunodiagnostics Market Analysis - Clinical Indication

8.1 Overview
8.2 Asia Pacific Immunodiagnostics Market Share by Clinical Indication - 2022 & 2030 (%)
8.3 Infectious Diseases:
- 8.3.1 Overview
- 8.3.2 Infectious Diseases: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.1 COVID-19
    - 8.3.2.1.1 Overview
    - 8.3.2.1.2 COVID-19: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.2 Tuberculosis
    - 8.3.2.2.1 Overview
    - 8.3.2.2.2 Tuberculosis: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.3 Lyme
    - 8.3.2.3.1 Overview
    - 8.3.2.3.2 Lyme: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.4 Infection Management
    - 8.3.2.4.1 Overview
    - 8.3.2.4.2 Infection Management: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.5 Zika
    - 8.3.2.5.1 Overview
    - 8.3.2.5.2 Zika: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.6 Treponema
    - 8.3.2.6.1 Overview
    - 8.3.2.6.2 Treponema: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.7 TORCH
    - 8.3.2.7.1 Overview
    - 8.3.2.7.2 TORCH: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.8 Measles and Mumps
    - 8.3.2.8.1 Overview
    - 8.3.2.8.2 Measles and Mumps: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.9 VZV
    - 8.3.2.9.1 Overview
    - 8.3.2.9.2 VZV: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.10 EBV
    - 8.3.2.10.1 Overview
    - 8.3.2.10.2 EBV: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.4 Hepatitis+HIV:
- 8.4.1 Overview
- 8.4.2 Hepatitis+HIV: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.5 Gastrointestinal
- 8.5.1 Overview
- 8.5.2 Gastrointestinal: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.6 Metabolic Disorders
- 8.6.1 Overview
- 8.6.2 Metabolics: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.7 Endocrinology
- 8.7.1 Overview
- 8.7.2 Endocrinology: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 8.7.3 Hypertension
  - 8.7.3.1 Overview
  - 8.7.3.2 Hypertension: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 8.7.4 Growth
  - 8.7.4.1 Overview
  - 8.7.4.2 Growth: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 8.7.5 Diabetes
  - 8.7.5.1 Overview
  - 8.7.5.2 Diabetes: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 8.7.6 Thyroid
  - 8.7.6.1 Overview
  - 8.7.6.2 Thyroid: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
- 8.7.7 Reproductive Endocrinology
  - 8.7.7.1 Overview
  - 8.7.7.2 Reproductive Endocrinology: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
8.8 Others
- 8.8.1 Overview
- 8.8.2 Others: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Immunodiagnostics Market Analysis - End User

9.1 Overview
9.2 Asia Pacific Immunodiagnostics Market Share by End User - 2022 & 2030 (%)
9.3 Hospitals
- 9.3.1 Overview
- 9.3.2 Hospitals: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.4 Clinics
- 9.4.1 Overview
- 9.4.2 Clinics: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.5 Diagnostic Laboratories
- 9.5.1 Overview
- 9.5.2 Diagnostic Laboratories: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.6 Academic and Research Institutes
- 9.6.1 Overview
- 9.6.2 Academic and Research Institutes: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
9.7 Others
- 9.7.1 Overview
- 9.7.2 Others: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Immunodiagnostics Market - Revenue and Forecast to 2030 - Country Analysis

10.1 Overview

11. Asia Pacific Immunodiagnostics Market -Industry Landscape

11.1 Overview
11.2 Inorganic Growth Strategies
- 11.2.1 Overview
11.3 Organic Growth Strategies
- 11.3.1 Overview

12. Company Profiles

12.1 Abbott Laboratories
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 F. Hoffmann-La Roche Ltd
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 DiaSorin SpA
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Danaher Corp
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Thermo Fisher Scientific Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 PerkinElmer Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 bioMerieux SA
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 Svar Life Science AB
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Siemens Healthcare GmbH
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About The Insight Partners
13.2 Glossary of Terms

List Of Tables

Table 1. China Immunodiagnostics Market, by Product - Revenue and Forecast to 2030 (US$ Million)
Table 2. China Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US$ Million)
Table 3. China Immunodiagnostics Market, by Clinical Indication - Revenue and Forecast to 2030 (US$ Million)
Table 4. China Immunodiagnostics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US$ Million)
Table 5. China Immunodiagnostics Market, by Endocrinology - Revenue and Forecast to 2030 (US$ Million)
Table 6. China Immunodiagnostics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 7. Japan Immunodiagnostics Market, by Product - Revenue and Forecast to 2030 (US$ Million)
Table 8. Japan Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US$ Million)
Table 9. Japan Immunodiagnostics Market, by Clinical Indication - Revenue and Forecast to 2030 (US$ Million)
Table 10. Japan: Immunodiagnostics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US$ Million)
Table 11. Japan Immunodiagnostics Market, by Endocrinology - Revenue and Forecast to 2030 (US$ Million)
Table 12. Japan Immunodiagnostics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 13. India Immunodiagnostics Market, by Product - Revenue and Forecast to 2030 (US$ Million)
Table 14. India Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US$ Million)
Table 15. India Immunodiagnostics Market, by Clinical Indication - Revenue and Forecast to 2030 (US$ Million)
Table 16. India: Immunodiagnostics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US$ Million)
Table 17. India Immunodiagnostics Market, by Endocrinology - Revenue and Forecast to 2030 (US$ Million)
Table 18. India Immunodiagnostics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 19. Australia Immunodiagnostics Market, by Product - Revenue and Forecast to 2030 (US$ Million)
Table 20. Australia Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US$ Million)
Table 21. Australia Immunodiagnostics Market, by Clinical Indication - Revenue and Forecast to 2030 (US$ Million)
Table 22. Australia: Immunodiagnostics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US$ Million)
Table 23. Australia Immunodiagnostics Market, by Endocrinology - Revenue and Forecast to 2030 (US$ Million)
Table 24. Australia Immunodiagnostics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 25. South Korea Immunodiagnostics Market, by Product - Revenue and Forecast to 2030 (US$ Million)
Table 26. South Korea Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US$ Million)
Table 27. South Korea Immunodiagnostics Market, by Clinical Indication - Revenue and Forecast to 2030 (US$ Million)
Table 28. South Korea: Immunodiagnostics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US$ Million)
Table 29. South Korea Immunodiagnostics Market, by Endocrinology - Revenue and Forecast to 2030 (US$ Million)
Table 30. South Korea Immunodiagnostics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 31. Rest of Asia Pacific Immunodiagnostics Market, by Product - Revenue and Forecast to 2030 (US$ Million)
Table 32. Rest of Asia Pacific Immunodiagnostics Market, by Chemiluminescence Immunoassays (CLIA)- Revenue and Forecast to 2030 (US$ Million)
Table 33. Rest of Asia Pacific Immunodiagnostics Market, by Clinical Indication - Revenue and Forecast to 2030 (US$ Million)
Table 34. Rest of Asia Pacific: Immunodiagnostics Market, by Infectious Diseases - Revenue and Forecast to 2030 (US$ Million)
Table 35. Rest of Asia Pacific Immunodiagnostics Market, by Endocrinology - Revenue and Forecast to 2030 (US$ Million)
Table 36. Rest of Asia Pacific Immunodiagnostics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
Table 37. Recent Inorganic Growth Strategies in the Asia Pacific immunodiagnostics market
Table 38. Recent Organic Growth Strategies in the Asia Pacific immunodiagnostics market
Table 39. Glossary of Terms, Asia Pacific Immunodiagnostics Market

List Of Figures

Figure 1. Asia Pacific Immunodiagnostics Market Segmentation
Figure 2. Asia Pacific Immunodiagnostics Market, by Country
Figure 3. Asia Pacific Immunodiagnostics Market Overview
Figure 4. Enzyme-Linked Immunosorbent Assays (ELISA) Segment Held Largest Share of Product Segment in Asia Pacific Immunodiagnostics Market
Figure 5. India Expected to Show Remarkable Growth During Forecast Period
Figure 6. Asia Pacific: PEST Analysis
Figure 7. Experts' Opinion
Figure 8. Asia Pacific Immunodiagnostics Market: Impact Analysis of Drivers and Restraints
Figure 9. Asia Pacific Immunodiagnostics Market - Revenue Forecast and Analysis - 2021-2030
Figure 10. Asia Pacific Immunodiagnostics Market, by Product, 2022 & 2030 (%)
Figure 11. Enzyme-linked Immunosorbent Assays (ELISA): Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 12. Chemiluminescence Immunoassays (CLIA): Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 13. Vitamin D Assay: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 14. HIV Detection: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 15. HIV Ag/Ab Combo Assay: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 16. Other Tests: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 17. Radioimmunoassays (RIA):Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 18. Others: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 19. Asia Pacific Immunodiagnostics Market Share by Clinical Indication - 2022 & 2030 (%)
Figure 20. Infectious Diseases: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 21. COVID-19: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 22. Tuberculosis: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 23. Lyme: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 24. Infection Management: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 25. Zika: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 26. Treponema: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 27. TORCH: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 28. Measles and Mumps: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 29. VZV: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 30. EBV: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 31. Hepatitis+HIV: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 32. Gastrointestinal: Asia Pacific Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 33. Metabolics: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 34. Endocrinology: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 35. Hypertension: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 36. Growth: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 37. Diabetes: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 38. Thyroid: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 39. Reproductive Endocrinology: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 40. Others: Asia Pacific Immunodiagnostics Market Revenue and Forecast to 2030 (US$ Million)
Figure 41. Asia Pacific Immunodiagnostics Market Share by End User - 2022 & 2030 (%)
Figure 42. Hospitals: Asia Pacific Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 43. Clinics: Asia Pacific Immunodiagnostics Market Revenue and Forecasts To 2030 (US$ Million)
Figure 44. Diagnostic Laboratories: Asia Pacific Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 45. Academic and Research Institutes: Asia Pacific Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 46. Others: Asia Pacific Immunodiagnostics Market Revenue and Forecasts to 2030 (US$ Million)
Figure 47. Asia Pacific: Immunodiagnostics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 48. Asia Pacific: Immunodiagnostics Market, by Country, 2022 & 2030 (%)
Figure 49. China: Immunodiagnostics market - Revenue and Forecast to 2030 (US$ Million)
Figure 50. Japan: Immunodiagnostics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 51. India: Immunodiagnostics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 52. Australia: Immunodiagnostics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 53. South Korea: Immunodiagnostics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 54. Rest of Asia Pacific: Immunodiagnostics Market - Revenue and Forecast to 2030 (US$ Million)